Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 5
2006 4
2007 10
2008 13
2009 11
2010 20
2011 29
2012 23
2013 10
2014 13
2015 17
2016 11
2017 8
2018 9
2019 9
2020 8
2021 7
2022 5
2023 6
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Results by year

Filters applied: . Clear all
Page 1
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Klos K, Bordelon Y, St Hiliare MH, Shprecher D, Lee S, Dawson TM, Roschke V, Kieburtz K. McGarry A, et al. Among authors: lee s. Lancet Neurol. 2024 Jan;23(1):37-45. doi: 10.1016/S1474-4422(23)00378-2. Lancet Neurol. 2024. PMID: 38101901 Clinical Trial.
Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics.
Griñán-Ferré C, Jarné-Ferrer J, Bellver-Sanchís A, Codony S, Puigoriol-Illamola D, Sanfeliu C, Oh Y, Lee S, Vázquez S, Pallàs M. Griñán-Ferré C, et al. Among authors: lee s. CNS Neurosci Ther. 2024 Apr;30(4):e14511. doi: 10.1111/cns.14511. Epub 2023 Oct 31. CNS Neurosci Ther. 2024. PMID: 37905690 Free PMC article.
The Effects of NLY01, a Novel Glucagon-Like Peptide-1 Receptor Agonist, on Cuprizone-Induced Demyelination and Remyelination: Challenges and Future Perspectives.
Gharagozloo M, Galleguillos D, Jank L, Sotirchos ES, Smith MD, Garton T, Kumar S, Hussein O, Potluri S, Taylor M, Siu C, Mace JW, Dawson T, Dawson VL, Lee S, Calabresi PA. Gharagozloo M, et al. Among authors: lee s. Neurotherapeutics. 2023 Jul;20(4):1229-1240. doi: 10.1007/s13311-023-01390-4. Epub 2023 Jun 9. Neurotherapeutics. 2023. PMID: 37296356 Free article.
202 results